Centessa Sales General And Administrative To Revenue from 2010 to 2024
| CNTA Stock | USD 17.16 0.65 3.94% |
Sales General And Administrative To Revenue | First Reported 2010-12-31 | Previous Quarter 7.06 | Current Value 6.27 | Quarterly Volatility 0.43974037 |
Check Centessa Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Centessa Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 11 M, Depreciation And Amortization of 5.5 M or Interest Expense of 10.4 M, as well as many indicators such as Price To Sales Ratio of 89.37, Dividend Yield of 0.0 or PTB Ratio of 3.4. Centessa financial statements analysis is a perfect complement when working with Centessa Pharmaceuticals Valuation or Volatility modules.
Centessa | Sales General And Administrative To Revenue |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Centessa Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Centessa Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Centessa Pharmaceuticals Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Centessa Pharmaceuticals Plc Stock:Check out the analysis of Centessa Pharmaceuticals Correlation against competitors. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Centessa Pharmaceuticals. If investors know Centessa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Centessa Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.52) | Revenue Per Share 0.065 | Return On Assets (0.20) | Return On Equity (0.43) |
The market value of Centessa Pharmaceuticals is measured differently than its book value, which is the value of Centessa that is recorded on the company's balance sheet. Investors also form their own opinion of Centessa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Centessa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Centessa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Centessa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Centessa Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Centessa Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Centessa Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.